JP2002503642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002503642A5 JP2002503642A5 JP2000525453A JP2000525453A JP2002503642A5 JP 2002503642 A5 JP2002503642 A5 JP 2002503642A5 JP 2000525453 A JP2000525453 A JP 2000525453A JP 2000525453 A JP2000525453 A JP 2000525453A JP 2002503642 A5 JP2002503642 A5 JP 2002503642A5
- Authority
- JP
- Japan
- Prior art keywords
- ptx3
- expression vector
- sequence
- amino acid
- long pentraxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 description 10
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 description 10
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 108700025763 PTX3 Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 101100352284 Homo sapiens PITX3 gene Proteins 0.000 description 3
- 101100031710 Homo sapiens PTX3 gene Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97A000796 | 1997-12-19 | ||
| IT97RM000796A IT1298487B1 (it) | 1997-12-19 | 1997-12-19 | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| PCT/IT1998/000364 WO1999032516A2 (en) | 1997-12-19 | 1998-12-16 | Pharmaceutical compositions containing the long pentraxin ptx3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002503642A JP2002503642A (ja) | 2002-02-05 |
| JP2002503642A5 true JP2002503642A5 (https=) | 2006-02-16 |
| JP4173633B2 JP4173633B2 (ja) | 2008-10-29 |
Family
ID=11405409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000525453A Expired - Fee Related JP4173633B2 (ja) | 1997-12-19 | 1998-12-16 | 長いペントラキシンｐｔｘ３を含む医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8003109B2 (https=) |
| EP (1) | EP1034185B1 (https=) |
| JP (1) | JP4173633B2 (https=) |
| KR (1) | KR100560085B1 (https=) |
| AT (1) | ATE295853T1 (https=) |
| AU (1) | AU756974B2 (https=) |
| CA (1) | CA2315277C (https=) |
| DE (1) | DE69830251T2 (https=) |
| ES (1) | ES2242309T3 (https=) |
| IT (1) | IT1298487B1 (https=) |
| NZ (1) | NZ505063A (https=) |
| PT (1) | PT1034185E (https=) |
| WO (1) | WO1999032516A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1298487B1 (it) | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
| IT1317930B1 (it) * | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
| US20040198655A1 (en) * | 2001-08-03 | 2004-10-07 | Alberto Mantovani | Use of long pentraxin ptx3 for treating female infertility |
| US7041648B2 (en) | 2001-08-03 | 2006-05-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Compositions and methods for treating female fertility |
| ITRM20020109A1 (it) * | 2002-02-28 | 2003-08-28 | Sigma Tau Ind Farmaceuti | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
| ITRM20020191A1 (it) * | 2002-04-08 | 2003-10-08 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att |
| ITRM20030596A1 (it) * | 2003-12-23 | 2005-06-24 | Sigma Tau Ind Farmaceuti | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
| ITRM20040223A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. |
| ITRM20040489A1 (it) * | 2004-10-08 | 2005-01-08 | Sigma Tau Ind Farmaceuti | Pentraxina lunga ptx3 deglicosilata o desialidata. |
| JP5427415B2 (ja) * | 2006-01-24 | 2014-02-26 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | Ｆｇｆ２結合性ペプチドおよびそれらの使用 |
| EP1832295A1 (en) | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
| PT2012816E (pt) * | 2006-05-02 | 2012-08-17 | Sigma Tau Ind Farmaceuti | Uso de timosina 1, isolada ou em combinação com ptx3 ou ganciclovir, para o tratamento da infeção por citomegalovírus |
| WO2009095403A1 (en) * | 2008-01-29 | 2009-08-06 | Tecnogen S.P.A. | Expression system and uses thereof for the production of human long pentraxin 3 |
| HRP20130947T1 (hr) | 2009-07-29 | 2013-11-08 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Poboljšani sustav za eksprimiranje ljudskog dugog pentraksina 3 i njegova upotreba |
| KR101305515B1 (ko) | 2011-06-10 | 2013-09-06 | 경북대학교 산학협력단 | 펜트락신 3 단백질의 파킨슨 질환 진단 용도 |
| WO2013191280A1 (ja) * | 2012-06-22 | 2013-12-27 | 国立大学法人 東京大学 | 全身性炎症反応症候群の治療又は予防剤 |
| TWI528969B (zh) * | 2013-06-07 | 2016-04-11 | 國立成功大學 | 胺基酸序列用於製備抑制ｐｔｘ３治療鼻咽癌之醫藥組合物之用途 |
| TWI531375B (zh) | 2015-05-29 | 2016-05-01 | 國立成功大學 | 抑制癌細胞活性之短肽治療劑及含此之醫藥組成物 |
| CN105132459B (zh) * | 2015-09-14 | 2019-01-29 | 武汉市星熠艾克生物医药有限责任公司 | 人类ptx3重组蛋白的制备方法及应用 |
| EP4103592A4 (en) * | 2020-02-12 | 2024-01-10 | BioTissue Holdings Inc. | METHODS OF DESTRUCTING OR INHIBITING THE GROWTH OF CANCER CELLS |
| US20230227511A1 (en) * | 2020-05-14 | 2023-07-20 | Nippon Medical School Foundation | Therapeutic or preventive agent for infectious disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1196564B (it) * | 1986-08-04 | 1988-11-16 | Sigma Tau Ind Farmaceuti | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche |
| JPH06506195A (ja) * | 1991-01-14 | 1994-07-14 | ニューヨーク ユニバシテイ | サイトカイン誘導タンパク質、ｔｓｇ−１４、そのためのｄｎａコード化およびその使用 |
| IT1254687B (it) * | 1992-04-14 | 1995-09-28 | Italfarmaco Spa | Gene inducibile da citochine |
| US6210941B1 (en) * | 1997-06-27 | 2001-04-03 | The Trustees Of Boston University | Methods for the detection and isolation of proteins |
| US5632983A (en) * | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| US5939423A (en) * | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
| IT1298487B1 (it) | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
| IT1317930B1 (it) * | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
| US6872541B2 (en) * | 2001-07-25 | 2005-03-29 | Coulter International Corp. | Method and compositions for analysis of pentraxin receptors as indicators of disease |
| US7041648B2 (en) * | 2001-08-03 | 2006-05-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Compositions and methods for treating female fertility |
| US20040198655A1 (en) * | 2001-08-03 | 2004-10-07 | Alberto Mantovani | Use of long pentraxin ptx3 for treating female infertility |
| US20040137544A1 (en) * | 2002-10-31 | 2004-07-15 | Roberto Latini | PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies |
| WO2004094991A2 (en) | 2003-04-23 | 2004-11-04 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| ITRM20030596A1 (it) * | 2003-12-23 | 2005-06-24 | Sigma Tau Ind Farmaceuti | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
| ITRM20040489A1 (it) * | 2004-10-08 | 2005-01-08 | Sigma Tau Ind Farmaceuti | Pentraxina lunga ptx3 deglicosilata o desialidata. |
| EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
| PT2012816E (pt) * | 2006-05-02 | 2012-08-17 | Sigma Tau Ind Farmaceuti | Uso de timosina 1, isolada ou em combinação com ptx3 ou ganciclovir, para o tratamento da infeção por citomegalovírus |
-
1997
- 1997-12-19 IT IT97RM000796A patent/IT1298487B1/it active IP Right Grant
-
1998
- 1998-12-16 PT PT98962665T patent/PT1034185E/pt unknown
- 1998-12-16 NZ NZ505063A patent/NZ505063A/xx not_active IP Right Cessation
- 1998-12-16 DE DE69830251T patent/DE69830251T2/de not_active Expired - Lifetime
- 1998-12-16 JP JP2000525453A patent/JP4173633B2/ja not_active Expired - Fee Related
- 1998-12-16 AT AT98962665T patent/ATE295853T1/de active
- 1998-12-16 ES ES98962665T patent/ES2242309T3/es not_active Expired - Lifetime
- 1998-12-16 KR KR1020007006739A patent/KR100560085B1/ko not_active Expired - Fee Related
- 1998-12-16 AU AU17829/99A patent/AU756974B2/en not_active Ceased
- 1998-12-16 EP EP98962665A patent/EP1034185B1/en not_active Expired - Lifetime
- 1998-12-16 WO PCT/IT1998/000364 patent/WO1999032516A2/en not_active Ceased
- 1998-12-16 CA CA2315277A patent/CA2315277C/en not_active Expired - Fee Related
-
2007
- 2007-07-31 US US11/882,180 patent/US8003109B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002503642A5 (https=) | ||
| US8003109B2 (en) | Pharmaceutical compositions containing the long pentraxin PTX3 | |
| CA2276450C (en) | A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent | |
| AU704910B2 (en) | Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF) | |
| CN109843902A (zh) | 用于B型肝炎病毒感染的RNAi剂 | |
| CA2308116A1 (en) | Low-toxicity human interferon-alpha analog | |
| CA2529179A1 (en) | Recombinant adeno-associated virus vector for treatment of alzheimer disease | |
| JP2003528827A5 (https=) | ||
| US9834764B2 (en) | Compositions and methods of using chondroitinase ABCI mutants | |
| SK43197A3 (en) | Method of treating diabetes mellitus using kgf | |
| JPH11504036A (ja) | ケモカイン結合タンパク質およびその使用 | |
| JP2004501650A5 (https=) | ||
| Terazaki et al. | An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice | |
| US20040224409A1 (en) | Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) | |
| CN109439612A (zh) | 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途 | |
| CA2073493A1 (en) | Recombinant marek's disease virus, process for preparing the same and vaccine containing the same | |
| JP2002516662A5 (https=) | ||
| CN116143950B (zh) | 一种抑制肿瘤侵袭转移的多肽组合及其应用 | |
| KR20040097249A (ko) | 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제 | |
| AU703793B2 (en) | Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) | |
| CN1277581C (zh) | 一种用蚕生产抗血栓药物的方法 | |
| CN113527509B (zh) | 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用 | |
| CN118634243B (zh) | Mir2911在制备抗登革病毒denv的药物中的应用 | |
| US8227404B2 (en) | Method of preventing acute or sub-acute hepatic failure in a subject by administering a soluble human tumor necrosis factor alpha fusion protein | |
| KR102946895B1 (ko) | SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도 |